2-methoxyestradiol (2-ME2) sulfation: Possible metabolic pathway

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

2-ME2 is an endogenous estrogen metabolite that inhibits the proliferation of breast and other human cancer cell lines. 2-ME2 also has potent anti-angiogenic and anti-tubulin properties, and it may inhibit estrogen-induced carcinogenesis in the mammary gland. We set out to test the hypothesis that 2-ME2 might be a substrate for sulfate conjugation and, therefore, that individual variations in the sulfation of 2-ME2 might contribute to individual differences in its metabolism, pharmacokinetics and therapeutic efficacy. As a first step, we tested 2-ME2 as a substrate for 1 human sulfotransferase (SULT) isoforms - as well as all of the common allozymes for SULT1A1 and 1A2. Substrate kinetic studies were conducted in two stages - starting with concentrations over 5 orders of magnitude, followed by determination of Km values over a narrow concentration range. 2-ME2 was a sulfate acceptor substrate for SULT1A1* 1, *2, *3; 1A2*1, *2, *3; 1A3; 1E1; 2A1; 2B1a and 2B1b, with apparent Km values of 2.5, 5.2, 1.6; 4.2, 111, 5.3; 91; 0.067; 8.3; 4.1 and 4.1 μM, respectively. These results suggest that individual pharmacogenetic variation in sulfate conjugation might contribute to individual differences in 2-ME2 pharmacokinetics and therapeutic effect.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001

Fingerprint

Metabolic Networks and Pathways
Sulfates
Individuality
Estrogens
Pharmacokinetics
Sulfotransferases
Pharmacogenetics
Therapeutic Uses
Human Mammary Glands
Tubulin
Isoenzymes
Protein Isoforms
Carcinogenesis
Breast
Cell Line
2-methoxyestradiol
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

2-methoxyestradiol (2-ME2) sulfation : Possible metabolic pathway. / Adjei, Alex; Wood, T. C.; Weinshilboum, Richard M.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

@article{b5d076125c8e4d9280543c3792696d91,
title = "2-methoxyestradiol (2-ME2) sulfation: Possible metabolic pathway",
abstract = "2-ME2 is an endogenous estrogen metabolite that inhibits the proliferation of breast and other human cancer cell lines. 2-ME2 also has potent anti-angiogenic and anti-tubulin properties, and it may inhibit estrogen-induced carcinogenesis in the mammary gland. We set out to test the hypothesis that 2-ME2 might be a substrate for sulfate conjugation and, therefore, that individual variations in the sulfation of 2-ME2 might contribute to individual differences in its metabolism, pharmacokinetics and therapeutic efficacy. As a first step, we tested 2-ME2 as a substrate for 1 human sulfotransferase (SULT) isoforms - as well as all of the common allozymes for SULT1A1 and 1A2. Substrate kinetic studies were conducted in two stages - starting with concentrations over 5 orders of magnitude, followed by determination of Km values over a narrow concentration range. 2-ME2 was a sulfate acceptor substrate for SULT1A1* 1, *2, *3; 1A2*1, *2, *3; 1A3; 1E1; 2A1; 2B1a and 2B1b, with apparent Km values of 2.5, 5.2, 1.6; 4.2, 111, 5.3; 91; 0.067; 8.3; 4.1 and 4.1 μM, respectively. These results suggest that individual pharmacogenetic variation in sulfate conjugation might contribute to individual differences in 2-ME2 pharmacokinetics and therapeutic effect.",
author = "Alex Adjei and Wood, {T. C.} and Weinshilboum, {Richard M}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - 2-methoxyestradiol (2-ME2) sulfation

T2 - Possible metabolic pathway

AU - Adjei, Alex

AU - Wood, T. C.

AU - Weinshilboum, Richard M

PY - 2001

Y1 - 2001

N2 - 2-ME2 is an endogenous estrogen metabolite that inhibits the proliferation of breast and other human cancer cell lines. 2-ME2 also has potent anti-angiogenic and anti-tubulin properties, and it may inhibit estrogen-induced carcinogenesis in the mammary gland. We set out to test the hypothesis that 2-ME2 might be a substrate for sulfate conjugation and, therefore, that individual variations in the sulfation of 2-ME2 might contribute to individual differences in its metabolism, pharmacokinetics and therapeutic efficacy. As a first step, we tested 2-ME2 as a substrate for 1 human sulfotransferase (SULT) isoforms - as well as all of the common allozymes for SULT1A1 and 1A2. Substrate kinetic studies were conducted in two stages - starting with concentrations over 5 orders of magnitude, followed by determination of Km values over a narrow concentration range. 2-ME2 was a sulfate acceptor substrate for SULT1A1* 1, *2, *3; 1A2*1, *2, *3; 1A3; 1E1; 2A1; 2B1a and 2B1b, with apparent Km values of 2.5, 5.2, 1.6; 4.2, 111, 5.3; 91; 0.067; 8.3; 4.1 and 4.1 μM, respectively. These results suggest that individual pharmacogenetic variation in sulfate conjugation might contribute to individual differences in 2-ME2 pharmacokinetics and therapeutic effect.

AB - 2-ME2 is an endogenous estrogen metabolite that inhibits the proliferation of breast and other human cancer cell lines. 2-ME2 also has potent anti-angiogenic and anti-tubulin properties, and it may inhibit estrogen-induced carcinogenesis in the mammary gland. We set out to test the hypothesis that 2-ME2 might be a substrate for sulfate conjugation and, therefore, that individual variations in the sulfation of 2-ME2 might contribute to individual differences in its metabolism, pharmacokinetics and therapeutic efficacy. As a first step, we tested 2-ME2 as a substrate for 1 human sulfotransferase (SULT) isoforms - as well as all of the common allozymes for SULT1A1 and 1A2. Substrate kinetic studies were conducted in two stages - starting with concentrations over 5 orders of magnitude, followed by determination of Km values over a narrow concentration range. 2-ME2 was a sulfate acceptor substrate for SULT1A1* 1, *2, *3; 1A2*1, *2, *3; 1A3; 1E1; 2A1; 2B1a and 2B1b, with apparent Km values of 2.5, 5.2, 1.6; 4.2, 111, 5.3; 91; 0.067; 8.3; 4.1 and 4.1 μM, respectively. These results suggest that individual pharmacogenetic variation in sulfate conjugation might contribute to individual differences in 2-ME2 pharmacokinetics and therapeutic effect.

UR - http://www.scopus.com/inward/record.url?scp=0009587678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0009587678&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0009587678

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -